We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) lost 6.3% in a month compared with the industry’s decline of 2.8%.
Earlier in the month, Regeneron delivered better-than-expected first-quarter 2023 results. However, lead drug Eylea (aflibercept) sales declined. Shares declined in response to the same.
Lead drug Eylea’s sales in the United States were $1.4 billion, down 6% year over year, primarily due to an increase in sales-related deductions. Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG (BAYRY - Free Report) .
Regeneron’s lead drug, Eylea, is approved for various ophthalmology indications and has been a consistent performer, but sales are under pressure due to increasing competition from Roche’s (RHHBY - Free Report) Vabysmo.
In January 2022, Roche won FDA approval for Vabysmo (faricimab-svoa) to treat wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A. The European Commission also approved Vabysmo (faricimab) for these indications.
Regeneron records net product sales of Eylea in the United States and Bayer records net product sales of Eylea outside the United States. Regeneron records its share of profits/losses in connection with sales of Eylea outside the United States.
On a positive note, the FDA accepted the biologics license application (BLA) for the priority review of aflibercept 8 mg for treating patients with wet AMD, DME and diabetic retinopathy, with a target action date of Jun 27, 2023.
A regulatory application has also been submitted for treating wet AMD and DME in the European Union (EU) and Japan. Regeneron is now focused on the potential launch of aflibercept 8 mg following a tentative approval.
Shares of Regeneron are still up 5.4% in the year so far against the industry’s decline of 7.8%.
Image Source: Zacks Investment Research
Regeneron’s top line is being boosted by its share of profits/losses in connection with global sales of Dupixent. Its partner, Sanofi (SNY - Free Report) , records global net product sales of Dupixent. Dupixent maintains its dominant position, driven by continued strong demand in the approved indications, atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis and prurigo nodularis.
Regeneron also records net product sales of Praluent in the United States and Sanofi records net product sales of Praluent outside the United States and pays the company a royalty on such sales.
Both companies recently announced that the U.S. Supreme Court ruled against Amgen, ending a nearly decade-long patent dispute related to Praluent. The decision affirms the United States Court of Appeals for the Federal Circuit’s opinion, which held that Amgen’s asserted U.S. PCSK9 patent claims were invalid.
Meanwhile, Regeneron is also looking to diversify in the lucrative oncology space with Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer.
Image: Bigstock
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) lost 6.3% in a month compared with the industry’s decline of 2.8%.
Earlier in the month, Regeneron delivered better-than-expected first-quarter 2023 results. However, lead drug Eylea (aflibercept) sales declined. Shares declined in response to the same.
Lead drug Eylea’s sales in the United States were $1.4 billion, down 6% year over year, primarily due to an increase in sales-related deductions. Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG (BAYRY - Free Report) .
Regeneron’s lead drug, Eylea, is approved for various ophthalmology indications and has been a consistent performer, but sales are under pressure due to increasing competition from Roche’s (RHHBY - Free Report) Vabysmo.
In January 2022, Roche won FDA approval for Vabysmo (faricimab-svoa) to treat wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A. The European Commission also approved Vabysmo (faricimab) for these indications.
Regeneron records net product sales of Eylea in the United States and Bayer records net product sales of Eylea outside the United States. Regeneron records its share of profits/losses in connection with sales of Eylea outside the United States.
On a positive note, the FDA accepted the biologics license application (BLA) for the priority review of aflibercept 8 mg for treating patients with wet AMD, DME and diabetic retinopathy, with a target action date of Jun 27, 2023.
A regulatory application has also been submitted for treating wet AMD and DME in the European Union (EU) and Japan. Regeneron is now focused on the potential launch of aflibercept 8 mg following a tentative approval.
Shares of Regeneron are still up 5.4% in the year so far against the industry’s decline of 7.8%.
Image Source: Zacks Investment Research
Regeneron’s top line is being boosted by its share of profits/losses in connection with global sales of Dupixent. Its partner, Sanofi (SNY - Free Report) , records global net product sales of Dupixent. Dupixent maintains its dominant position, driven by continued strong demand in the approved indications, atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis and prurigo nodularis.
Regeneron also records net product sales of Praluent in the United States and Sanofi records net product sales of Praluent outside the United States and pays the company a royalty on such sales.
Both companies recently announced that the U.S. Supreme Court ruled against Amgen, ending a nearly decade-long patent dispute related to Praluent. The decision affirms the United States Court of Appeals for the Federal Circuit’s opinion, which held that Amgen’s asserted U.S. PCSK9 patent claims were invalid.
Meanwhile, Regeneron is also looking to diversify in the lucrative oncology space with Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer.
Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.